Member Info for Wigwammer

Sorry this doesn’t make sense. They have the funding so why do it again? The last raise was 15 months ago. Please let’s keep it sensible … IMO DYOR GLA

Agree syno. I suspect use of the filter will help longer term gains. IMO DYOR GLA

The “bears were in charge” in both early January 2025 and early September 2025. In both those cases, positive news appeared out of the blue and the shares multiplied within days. If you miss those aggressive positive reversal days then your return gets cut to the bone (just one of the many reasons TA and trading in/out doesn’t work very well). IMO DYOR GLA

Yes. Funding is secured and that’s positive news. Nobody knows exactly when the deal is coming, but if you believe in the science and feel the valuation is compelling, the sensible thing to do is to hold the stock. Turn off the noise and be patient. IMO DYOR Good luck IMMers

My intention here isn’t to single out any member of the management team. I’m sure each of them has their own strengths, weaknesses, successes, and regrets - that applies to everyone, including Tim McCarthy and Professor Zimmer. What I’m highlighting is the apparent double standard: one poster seems perfectly comfortable repeatedly targeting a single individual, while overlooking things elsewhere… On the point about “genuine people” - I don’t doubt that nolupus believes he’s calling out something he sees as questionable. But what he misses is how his own behaviour comes across to the average poster. When someone posts relentless criticism day in, day out, questions others motives, keeps his own position as opaque as possible, and has done so for 8 years, then it’s entirely predictable that people eventually question HIS motives for being here…Simply saying you are “genuine” doesn’t make it so, I’m afraid… IMO GLA DYOR

You’re deflecting again, nolupus. This isn’t about 8 year old trial messages - it’s about your defence of zimmer while attacking other management… Why the double standards? What’s your motive? … Zimmer was the CSO and President during a poorly designed and executed trial. As you stated, he had been given a large holding in the company. Is it possible that if he had ceded more of that holding - shown willingness to share more of the upside - that a partner could have been secured, with better funding and stronger trial design? … IMO DYOR GLA

Very odd that nolupus will happily sit here 24/7 criticising management, but gets extremely defensive when Zimmer is mentioned. Zimmer was the President and Chief Scientific Officer at the time of the poorly designed and underfunded initial phase 3 trial… “You who believes so much much in the science and yet you say nothing when Dr Zimmer is treated like that..”… Very odd indeed. IMO DYOR GLA

It isn’t about your record or boasting about your portfolio, scrodingerscat - it’s about helping people here manage risk and return. The outcome speaks for itself: one approach locked in gains and reduced risk, the other rode it all the way down… There’s no irony in suggesting patience while selling some of my shares, because I still retained a highly material position - that’s simply good risk management… Your claim that I announced sells “much later” is just made up - i traded and announced the same morning. Making things up just makes you sound desperate… And nobody prompted your attack on me this morning, which is an odd move given that you don’t have a very strong hand. Seems I must have got right under your skin… IMO DYOR GLA

You can dress this up however you like, scrodingerscat, but the outcome speaks for itself. One approach locked in gains and reduced risk, the other stayed fully exposed and rode it all the way down. Staying fully exposed to a risky asset that consequently halves in value is generally NOT considered good risk management, and beware of boastful accountants who suggest otherwise.. IMO DYOR GLA

Despite your repeated boasts about your experience and ability, scrodingerscat, you have proven to be very naive. Timelines in biotech change, it is inherently risky, I have been repeatedly vocal on this point. Which is why I and others took profit at a much higher valuation. That is called smart risk management and worth listening to… By contrast, people should be wary of boastful accountants like scrodingerscat, who don’t manage their risk well and are naive to such realities.. IMO DYOR GLA

Thanks for confirming, Rog — Immupharma aren’t in a closed period today, though tomorrow… who knows? As per recent tradition, your posts are a masterclass in negativity and confirmation bias — basically a mirror of your mood and agenda. And no doubt the same vibe ran through your messages to Lisa and your take on her replies. IMO DYOR GLA

So immupharma isn’t in a closed period today, roger, but they could be tomorrow, right? It seems this information is only helpful if you are planning to check with the company every single day… GLA DYOR IMO

Yes … ATB

This feels like another one of your trademark long, confident conclusions roger, built on very little that’s actually concrete. The “100% certain” line—especially based on emails with Lisa—is where it really falls down. She’s Head of IR, not your personal deal hotline. She is not going to disclose inside information to you, me, or anyone else, directly or otherwise.. So let’s be realistic: that’s not what happened. What’s far more likely is that she gave careful, compliant, non-committal answers to your long, loaded emails —as she’s required to—and you’ve chosen to interpret that in the most negative way possible. That says more about your starting position than it does about the actual situation.. And that’s kind of the pattern with you. You don’t hold the stock, you’ve been aggressively negative in recent weeks, and every ambiguous signal gets filtered into a definitive bearish conclusion. NDAs? Doesn’t matter. Seven months of DD? Spun as failure. Positive presentation with CSO suggesting external scientists are engaged and impressed? Ignored. It’s always one-way traffic… These things take time—especially in biotech—and they’re rarely signposted in a way that retail investors can track in real time. IMO DYOR GLA

Quite right arthurgard. Get the resolutions passed, secure the cash, strengthen the balance sheet for partnering discussions, and move the pipeline forward. Sounds like an intelligent and genuine opinion. IMO DYOR GLA

It’s pretty clear that a frank, honest debate with you nolupus, is a non-starter. Posters such as oscar and myself have repeatedly and thoughtfully answered your questions. But the moment anything comes back your way, it’s tumbleweed.. You’ve sidestepped my question again this morning, which is becoming less of a surprise and more of a tradition. After enough rounds of this, people stop calling it debate and start calling it a waste of time. Good luck genuine IMMers

But the science at immupharma led by Sebastien Goudreau has led to new research verified by Jackson labs, a refreshed patent estate application through HLK, and broadening targets for P140 and the wider pipeline. Immupharma gets funded while other biotechs fall by the wayside, and for good reason. IMO DYOR GLA

The amusing thing is that - despite inventing a dozen imaginary things to worry about on a daily basis - none of the astute sceptics even mentioned the May going concern hurdle until AFTER the new

agreement was announced. And even then, only because I mentioned it first… This point will rangle them, but unfortunately it is true. The discussion would probably be better informed if they didn’t fill the “risk” side of things with nonsense each day, and instead left it to holders more capable of giving an informed view… IMO DYOR Good luck IMMers!

The nolupus/halfbutt thing goes back 8 years… Nuts 🔩🥜🌰

But they aren’t nolupus, and we both know it 🧐😂